|Bid||20.05 x 1000|
|Ask||24.60 x 800|
|Day's Range||23.50 - 24.40|
|52 Week Range||13.04 - 32.88|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.33|
Kiniksa Pharmaceuticals, Ltd. (KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across various stages of development, today announced an active investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for a clinical study of mavrilimumab in subjects with giant cell arteritis (GCA). U.S. subjects will be included in the ongoing, global Phase 2 clinical trial, in which dosing has already commenced in multiple countries.
HAMILTON, Bermuda, Dec. 17, 2018 -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 37th Annual J.P. Morgan Healthcare Conference on.
Kiniksa Pharmaceuticals, Ltd. (KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline consisting of five product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions, today announced that the U.S. Food and Drug Administration (FDA) requested additional information regarding the delivery device to be used in the company’s Phase 2 clinical trial of mavrilimumab in giant cell arteritis. In light of its device-related information request, the FDA placed the company’s recently-submitted investigational new drug application (IND) on clinical hold.
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
– Rilonacept pivotal Phase 3 clinical trial initiating this year– Mavrilimumab pre-IND meeting complete; plans for global Phase 2 clinical trial advancing– KPL-716 advancing.
In this analysis, my focus will be on developing a perspective on Kiniksa Pharmaceuticals Ltd’s (NASDAQ:KNSA) latest ownership structure, a less discussed, but important factor. A company’s ownership structure isRead More...